Published in Haematologica on August 01, 2014
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 8.18
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet (2008) 4.37
From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer (2009) 4.15
To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof (2002) 3.11
Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol (2008) 2.93
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet (2010) 2.45
Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood (2007) 2.16
Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst (1999) 2.13
MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol (2008) 1.91
A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res (2005) 1.90
microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood (2010) 1.70
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell (2010) 1.49
Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia. Leuk Res (2009) 1.43
MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis (2007) 1.35
Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Perspect Biol (2009) 1.30
Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. Blood (2012) 1.26
Importance of genetics in chronic lymphocytic leukemia. Blood Rev (2011) 1.09
Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma (2009) 0.99
MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL. Int J Cancer (2011) 0.92
The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia. Haematologica (2008) 0.92
Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma (2009) 0.90
MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia. Eur J Haematol (2010) 0.86
TP53 codon 72 polymorphism in patients with chronic lymphocytic leukaemia: identification of a subgroup with mutated IGHV genes and poor clinical outcome. Br J Haematol (2011) 0.83
Common genetic variation contributes significantly to the risk of developing chronic lymphocytic leukemia. Haematologica (2012) 0.83
Purine antagonists for chronic lymphocytic leukaemia. Cochrane Database Syst Rev (2006) 0.82
Timing of first-line cancer treatments - early versus late - a systematic review of phase III randomized trials. Cancer Treat Rev (2010) 0.80
p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia. Cancer Genet Cytogenet (2007) 0.79
Impact of the host genetic background on prognosis of chronic lymphocytic leukemia. Blood (2010) 0.78
MDM2 promotor polymorphism and disease characteristics in CLL. Leuk Res (2009) 0.77
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol (2015) 2.44
Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia (2014) 1.81
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia (2012) 1.68
Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest (2012) 1.64
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. Lancet Oncol (2015) 1.47
TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia (2010) 1.15
Immunoglobulin sequence analysis and prognostication in CLL: guidelines from the ERIC review board for reliable interpretation of problematic cases. Leukemia (2011) 1.10
Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica (2014) 0.97
Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting. Haematologica (2014) 0.96
Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing. Clin Cancer Res (2015) 0.96
Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. Elife (2014) 0.95
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol (2016) 0.92
Immunogenetic studies of chronic lymphocytic leukemia: revelations and speculations about ontogeny and clinical evolution. Cancer Res (2014) 0.87
Telomere dysfunction and chromothripsis. Int J Cancer (2016) 0.86
Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia. Haematologica (2016) 0.85
Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis. Hematology Am Soc Hematol Educ Program (2014) 0.85
Epigenetic silencing of miR-708 enhances NF-κB signaling in chronic lymphocytic leukemia. Int J Cancer (2015) 0.84
All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study. Ann Hematol (2016) 0.84
Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go? Haematologica (2016) 0.81
Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia. Leuk Lymphoma (2013) 0.81
Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance. Blood (2014) 0.81
Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival. Oncotarget (2015) 0.80
RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications. Haematologica (2016) 0.79
Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable Neuroblastomas. Cancer Res (2016) 0.79
The spectrum of genetic defects in chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis (2012) 0.78
Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference. Haematologica (2016) 0.78
Alterations of microRNA and microRNA-regulated messenger RNA expression in germinal center B-cell lymphomas determined by integrative sequencing analysis. Haematologica (2016) 0.77
Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. Br J Haematol (2014) 0.76
Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study. Drug Des Devel Ther (2015) 0.76
T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica (2016) 0.76
Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. Br J Clin Pharmacol (2015) 0.76
Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Res (2017) 0.75
Richter syndrome: pathogenesis and management. Semin Oncol (2016) 0.75
Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations. Haematologica (2014) 0.75
Krüppel-like factor 4 (KLF4) inactivation in chronic lymphocytic leukemia correlates with promoter DNA-methylation and can be reversed by inhibition of NOTCH signaling. Haematologica (2016) 0.75
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. Haematologica (2016) 0.75
Identifying Prognostic SNPs in Clinical Cohorts: Complementing Univariate Analyses by Resampling and Multivariable Modeling. PLoS One (2016) 0.75
ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres. Haematologica (2016) 0.75
Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome. Oncotarget (2015) 0.75
XIII. Molecular pathogenesis of transformed lymphomas. Hematol Oncol (2015) 0.75
Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia? Curr Hematol Malig Rep (2015) 0.75
Pharmacological Inhibition of Centrosome Clustering by Slingshot-Mediated Cofilin Activation and Actin Cortex Destabilization. Cancer Res (2016) 0.75
Which patients to sample in clinical cohort studies when the number of events is high and measurement of additional markers is constrained by limited resources. Cancer Med (2020) 0.75
EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. Lancet Haematol (2017) 0.75
Comparison of Different Stem Cell Mobilization Regimen in AL Amyloidosis Patients. Biol Blood Marrow Transplant (2017) 0.75
Nitric Oxide Metabolites and Lung Cancer Incidence: A Matched Case-Control Study Nested in the ESTHER Cohort. Oxid Med Cell Longev (2019) 0.75
Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function. Hematol Oncol (2015) 0.75
Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy. Int J Cancer (2016) 0.75
Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification. Haematologica (2017) 0.75
Cancer Genetics May Aid Diagnostics of Developmental Disorders. Hum Mutat (2016) 0.75
Lenalidomide/Melphalan/Dexamethasone in newly diagnosed patients with AL Amyloidosis: results of a prospective phase 2 study with long-term follow-up. Haematologica (2017) 0.75
Transcriptome Profiling of Adipose Tissue Reveals Depot-Specific Metabolic Alterations Among Patients with Colorectal Cancer. J Clin Endocrinol Metab (2019) 0.75
Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease. PLoS One (2017) 0.75
Molecular deregulation of signaling in lymphoid tumors. Eur J Haematol (2015) 0.75